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Dear Editor,
All-trans retinoic acid (ATRA) has become the mainstay in
the treatment of acute promyelocytic leukemia (APL)
because addition of ATRA to anthracyclines has been
shown to improve disease-free survival and overall survival
compared to chemotherapy alone [1]. ATRA induces the
differentiation of leukemic promyelocytes into mature cells
via its effect on the promyelocytic leukemia–retinoic acid
receptor fusion gene product, which results from the
translocation of chromosomes 15 and 17, characteristic for
APL.
ATRA therapy can be complicated by the ATRA
syndrome, first described by Frankel et al. [2]a n d
consisting of respiratory distress (89%), pulmonary infil-
trates (81%), fever (81%), bodyweight gain (50%), pleural
effusion (47%), renal failure (39%), pericardial effusion
(19%), cardiac failure (17%), and/or hypotension (12%). It
occurs in about 25% of APL patients treated with ATRA
monotherapy and in about 10–15% when combined with
chemotherapy [2–4]. This syndrome typically starts within
the first 21 days, with a median of 7–12 days [5]. In case of
ATRA syndrome, retinoic acid should be discontinued and
dexamethasone instituted.
We recently observed two nearly similar cases of
isolated, symptomatic ATRA-induced myocarditis. Both
patients had newly diagnosed t(15;17) positive APL and a
negative cardiac history and were treated with ATRA in
combination with idarubicin.
Patient 1, a 34-year-old woman, developed fever and
cardiac pain (without skeletal muscle pain) on days 19 and
21, respectively. Physical examination showed no abnor-
malities. The electrocardiogram revealed ST elevations in
most leads, and laboratory analysis showed a white blood
cell count (WBC) of 1.1×10
9/l, a creatine kinase (CK) of
798 U/l (normal value <190 U/l), and CK-MB of 116
μg/l (normal value <6.5 μg/l) (Fig. 1). On echocardiogra-
phy a pattern of perimyocarditis with minimal pericardial
effusion was seen. ATRA was discontinued but dexameth-
asone was withheld because at that time point viral
myocarditis could not be ruled out (later all serological
tests for viral infections proved to be negative). The patient
recovered uneventfully. ATRA was reintroduced in the
following cycles of consolidation chemotherapy, which
consisted of subsequent cycles with idarubicin and ATRA,
mitoxantrone and ATRA, and idarubicin and ATRAwithout
side effects. The patient achieved sustained molecular
complete remission (follow-up more than 60 months) with
a maintenance therapy consisting of 6-mercaptopurine,
ATRA, and methotrexate once weekly during 2 years.
Patient 2, a 46-year-old man, became febrile, hypotensive,
and complained of a constant left thoracic pain (not related to
respiration) on days 23 and 24 after the initiation of ATRA.
There was no skeletal muscle pain. Apart from profuse
sweating, physical examination was normal. The electrocar-
diogram showed ST elevations in most leads consistent with
pericarditis. Laboratory analysis showed a WBC of 0.3×10
9/l,
CK 1,643 U/l, and CK-MB 144 g/l (Fig. 2). Echocardiog-
raphy and cardiac MRI showed a pattern of myocarditis with
generalized abnormal wall movement, without pericardial
effusion. ATRA was discontinued and dexamethasone was
withheld because at that time point viral myocarditis could
not be ruled out (also, in this patient, later all serological
tests for viral infections proved to be negative). The patient
recovered uneventfully and cardiac function normalized. In
this patient, ATRA was reintroduced uneventfully in the
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cytarabin plus ATRA, mitoxantrone plus ATRA, and
idarubicin, cytarabin plus ATRA. Complete molecular
remission was achieved (follow-up 6 months) and mainte-
nance therapy consisting of 6-mercaptopurine, ATRA, and
methotrexate once weekly for a period of 2 years was
initiated.
In both cases a diagnosis of isolated ATRA-induced
myocarditis was made, as symptoms disappeared sponta-
neously when ATRA was discontinued and no other causes
for myocarditis could be found.
The two cases reported here are important because the
myocarditis was not only symptomatic but was also
diagnosed in the absence of any symptoms or signs of the
ATRA syndrome. To our knowledge, just one case of
ATRA-induced generalized myositis with cardiac involve-
ment has been reported [6]. Although in that case no
myocarditis-related clinical signs or symptoms were pres-
ent, electrocardiogram and echocardiography were consis-
tent with the diagnosis of cardiac myocarditis. There have
been no previous reports of ATRA-induced isolated
symptomatic myocarditis.
Whether the myocarditis is part of the ATRA syndrome
or toxicity-related is difficult to differentiate. The patho-
genesis of the ATRA syndrome is not yet fully understood,
but it is believed to be due to leukocyte infiltration and
cytokine release causing endothelial damage and extrava-
sation of APL cells upon maturation induction by ATRA
treatment [3]. Necropsy of a patient with severe and fatal
ATRA syndrome revealed extensive organ infiltration by
the malignant cells, including myocardial involvement [7].
In that specific case, the patient had no cardiac complaints
and the leukocyte count was high. In both our cases WBCs
were low, making massive leukocyte infiltration a less
likely cause of myocarditis. Indeed, in a series of patients
with ATRA syndrome, leukocytosis was absent in one third
of the patients.
In conclusion, we present two cases of ATRA-induced,
isolated, symptomatic myocarditis. Both our patients
recovered completely without the use of steroids and were
subsequently retreated with ATRA without recurrence of
the myocarditis.
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Fig. 2 Case 2
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Fig. 1 Case 1
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